Dias RRS, Bomm L, Azevedo A, Souto SR, Lago OD

Idioma: Portugués
Referencias bibliográficas: 11
Paginas: 120-122
Archivo PDF: 65.89 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jorizzo JL, Carroll CL, Sangueza OP. Dermatomyositis. In: Bolognia JL, Jorizzo JL, Rapini RP, editores. Dermatology. 2nd ed. Spain: Mosby Elsevier; 2008, pp. 575-83.

2. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002; 20: 387-408.

3. Dourmishev LA, Dourmishev, AL. Dermatomyositis – Advances in recognition, undertanding and management. Springer Publishing, 2009.

4. Madan V, Chinoy H, Griffiths CEM, Cooper RG. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009; 34: 451-5.

5. Madan V, Chinoy H, Griffiths CEM, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Clin Exp Dermatol 2009; 34: 461-5.

6. Fiorentino D, Werth VP. Dermatomyositis autoantibodies. Arch Dermatol 2011; 174: 492-4.

7. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46: 25-8.

8. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol 2008; 59: 872-80.

9. Ruiz-Genao DP, Sanz-Sánchez T, Bartolomé- González B, Fernández-Herrera J, García-Díez A et al. Dermatomyositis-like reaction induced by chemotherapeutical agents. Int J Dermatol 2002; 41: 885-7.

10. Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D et al. Etanercept-induced anti-Jo-1-antibody-positive polymiositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010; 29: 563-6.

11. Klein R, Rosenbach M Kim EJ, Kim B, Werth VP, Dunham J et al. tumour necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010: 146: 780-4.